Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate. Konstantinou MP, Tournier E. Int J Dermatol 2022 May 15. doi: 10.1111/ijd.16269.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Konstantinou MP, Tournier E. Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate. Int J Dermatol 2022 May 15. doi: 10.1111/ijd.16269.
PMID: 35569068